SG
ENGNW icon

StoneX Group’s enGene Therapeutics Warrants ENGNW Stock Holding History

StoneX Group’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.92K Buy
+10,371
New +$10.8K ﹤0.01% 1370

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

StoneX Group's ENGNW Position: Q2 2026 in Review

StoneX Group opened a new position in enGene Therapeutics Warrants (ENGNW) in Q2 2026: 10,371 shares worth $8.92K. The stake represents ﹤0.01% of the portfolio and ranks #1370 among its holdings.

11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • StoneX Group held 10,371 shares of enGene Therapeutics Warrants worth $8.92K as of Q2 2026.
  • enGene Therapeutics Warrants was a new StoneX Group position in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1370 holding.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.